Optometry Advisor’s Post

The secret is out about Lacrifill, an #FDA-cleared #dryeyedisease therapy. So, who better to celebrate with than Darrell White, MD? Read Dr. White's thoughts about Lacrifill, which will be marketed by Nordic Pharma, in his latest Healio blog post. Find out why he's excited for this promising treatment and what benefits it may offer patients and #ophthalmologists. 🔗 below: #OcularSurgeryNews #Cornea #Eyedrops https://lnkd.in/ekBP-HS2

#SECO2024: Phentolamine ophthalmic solution 0.75% has secured US Food and Drug Administration (FDA) approval for reversing pharmacologically-induced pupil dilation after demonstrating efficacy in 2 phase 3 clinical trials. Poster presented at the SECO International Conference. The poster presenter, Justin Schweitzer, OD, FAAO, of Vance Thompson Vision in South Dakota, highlights the advantage this therapy offers by stressing that, “[p]upil dilation for ophthalmic examination has unwanted effects on vision, including photophobia, glare, and cycloplegia, which can last for up to 24 hours.” Read more: https://brnw.ch/21wHAxJ #Pupil #PupilDilation #ClinicalTrials #OphthalmicExamination #Vision #Photophobia #Glare #Cycloplegia #Optometry #EyeCare #EyeHealth

Three posters presented at the ASHP Midyear Clinical Meeting delved deeper into perioperative #painmanagement. https://lnkd.in/eEXciDm8 #Pharmacy #PharmacyEducation Drug Topics

Per the article: Where do manufacturers receive their perinatal tissue (suppliers) and should they be considered drugs? Also, according to paragraph 17 in the article, the FDA does not appear consistent when applying the "Homologous" rules for specifically orthopedic treatments. Homologous means similar origin, similar function in the target tissue. The umbilical cord is made of a cartilaginous, jelly-like (Wharton's Jelly) material that has a cushioning effect. When you inject that "jelly" in an arthritic knee, for example, worst case, it will help to cushion that knee and hopefully best case, signal repair and possible regeneration of the damaged cartilage. Just using the worst case scenario, that's homologous use, ie., cushioning the umbilical cord vein = cushioning your knee.

Market Scope estimates that nearly 2,000 vitrectomy machines were sold globally in 2023. Looking forward, however, the percentage of United States retinal surgeons planning to purchase a new vitrectomy machine in the next 12 months continues to fall, down to only 2 percent in 2023 from a high of 6 percent in 2020. The main growth drivers for vitrectomy machines are typically technology upgrades, surgery center expansion, market penetration, and replacements. However, it’s possible a recent acquisition could prove to be a driver on its own. ZEISS Medical Technology’s December acquisition of DORC Dutch Ophthalmic Research Center (International) combines the strong reputation of the Eva vitrectomy machine with Zeiss’ status as a global market leader with extensive financial resources and established sales networks—all while filling the biggest void in Zeiss’ product line. Will this acquisition convince more surgeons it’s time to purchase a new machine? We will be closely monitoring this and much more in our Ophthalmic Market Trends—Quarterly US Retina Edition.      These concise, unbiased expert-reviewed, survey-based editions are published every quarter to drive innovation and uncover competitive intelligence. Coverage includes vitrectomy volume and locations, vitrectomy machine use and market share, reusable and disposable instruments, visualization agents, IVT injections by disease and product, DME treatments, corticosteroid use, and photocoagulation volume and usage. Please visit https://bit.ly/Q223OMT4 to learn more about these trends and subscribe, or email matthew@market-scope.com to request a sample. #Vitrectomy #Machine #RetinalSurgery #PurchasePlans #MarketDrivers #Ophthalmology #Ophthalmic

AZR-MD-001 could redefine the standard of care in treating Contact Lens Discomfort and other ocular surface diseases -- learn more about our recent positive Ph. 2 data in my interview with @PharmaLeaders.com below.   #Ophthalmology #Optometry #ContactLenseDiscomfort #MeibomianGlandDysfunction #MGD #BioPharma  

Check out the latest report from IMIR Market Research Pvt. Ltd. on the 𝗘𝗹𝗲𝗰𝘁𝗿𝗼𝘀𝘂𝗿𝗴𝗶𝗰𝗮𝗹 𝗗𝗲𝘃𝗶𝗰𝗲𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 Outlook and Geography Forecast till 2028 Don't miss out on this opportunity to stay informed about the latest trends in the industry. Electrosurgical Devices Market Size, Share & Trends Analysis Report By Product (Electrosurgical generator, Electrodes Smoke, evacuation system, Accessories), By Application (Cardiovascular surgery, Cosmetic surgery, Neurosurgery, General surgery, Gynaecology Urology, Orthopaedic surgery, Others), By End-use (Hospitals Ambulatory surgical, units Specialized clinics, Others), COVID-19 Impact Analysis, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022 - 2028. 📚 𝐆𝐞𝐭 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐚𝐭 𝐝𝐢𝐬𝐜𝐨𝐮𝐧𝐭𝐞𝐝 𝐩𝐫𝐢𝐜𝐞:👇 https://lnkd.in/dGi7tzwB 📚𝐓𝐨𝐩 𝐌𝐨𝐫𝐞 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐀𝐫𝐞::👇 Applied Medical  AtriCure, Inc. BKK B. Braun Melsungen AG Boston Scientific CONMED Corporation ELLMAN INTERNATIONAL (UK) LIMITED. Erbe Group  Ethicon, Inc.  Johnson & Johnson  KARL STORZ  KLS Martin Group Medtronic MEGADYNE MEDICAL PRODUCTS INC. Olympus Corporation PLASMA SURGICAL LIMITED Smith & Nephew Group Plc Stryker Symmetry Surgical. Utah Medical Products, Inc.

Luke Seesink broke down a study that explored what's in the bottles of compounded low-dose atropine. He wrote: "According to this study, there is significant variability in the quality and consistency of compounded 0.01% atropine ophthalmic solutions across different compounding pharmacies in the U.S. This inconsistency in formulation, concentration, pH, and osmolarity could potentially pose risks to the efficacy and safety of these solutions in pediatric myopia management. "This research underscores the important role of regulatory oversight and quality assurance in the pharmaceutical compounding industry, especially for medications used in pediatric care. It’s crucial to ensure that compounded medications meet the required standards of quality and safety for the health and well-being of patients, especially children." Read the full report here: https://lnkd.in/eDyx8EAv #myopia #optometry #eyehealthcare #eyehealth #myopiamanagement #myopiacontrol #children #contactlenses #ophthalmology #orthokeratology #optometrist #orthokeratologist #optometricphysician #pediatrician

This is such an important topic in pediatric patients. Highly insightful article. #myopia #myopiamanagement #myopiacontrol #optometry #optometrist #ophthalmology #ophthalmologist

Innovative dECM Scaffolds in Regenerative Endodontic Procedures: A Systematic Review A recent systematic review examined the use of decellularized extracellular matrix (dECM) scaffolds in regenerative endodontic procedures (REPs) for tissue regeneration. The review assessed histological outcomes and factors impacting efficacy. The study used comprehensive search methods and included 17 relevant articles out of 387. The findings suggested that dECM scaffolds have the potential to promote tissue regeneration, but variations in methodology and delivery methods led to a high risk of bias. The study calls for standardization and improved protocols in future research to ensure reliable results. The review also highlights the potential of dECM scaffolds in dentin-pulp regeneration, but emphasizes the need for cautious interpretation and further rigorous studies. For more details please click the link! https://lnkd.in/d4YyuDiW #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical